2007
DOI: 10.1590/s0482-50042007000600012
|View full text |Cite
|
Sign up to set email alerts
|

Amiloidose manifestando-se com pseudo-hipertrofia muscular

Abstract: RESUMOAmiloidose tipo AL é uma doença rara causada pela deposição extracelular de fragmentos de cadeias leves monoclonais em órgãos e tecidos. Pode apresentar-se com uma ampla variedade de sinais e sintomas, e o acometimento cutâneo-muscular, simulando pseudo-hipertrofia muscular, é um achado muito raro. São descritos dois casos que apresentaram tal manifestação. Caso 1 -Mulher, 61 anos, há quatro meses com história de mialgia e aumento da massa muscular nas cinturas pélvica, escapular e região cervical. Não h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2010
2010
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“…Due to the possibility of controlling the inflammatory activity, anti-TNF agents represent and alternative treatment of secondary types. 6,7 The Brazilian Journal of Rheumatology has published three cases of amyloidosis, two on primary amyloidosis 3,8 and one secondary to hemodialysis, 9 over the last ten years. The objective of this report was to illustrate secondary renal amyloidosis as a rare complication of RA, and to discuss the use of anti-TNFα (etanercept) agents as a new therapeutic perspective.…”
Section: Introductionmentioning
confidence: 99%
“…Due to the possibility of controlling the inflammatory activity, anti-TNF agents represent and alternative treatment of secondary types. 6,7 The Brazilian Journal of Rheumatology has published three cases of amyloidosis, two on primary amyloidosis 3,8 and one secondary to hemodialysis, 9 over the last ten years. The objective of this report was to illustrate secondary renal amyloidosis as a rare complication of RA, and to discuss the use of anti-TNFα (etanercept) agents as a new therapeutic perspective.…”
Section: Introductionmentioning
confidence: 99%